{
    "clinical_study": {
        "@rank": "82482", 
        "acronym": "PUNiDIA", 
        "arm_group": {
            "arm_group_label": "E.-coli-Nissle", 
            "arm_group_type": "Experimental", 
            "description": "10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd"
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to\n      antidiabetic standard care in patients with diabetes mellitus type II"
        }, 
        "brief_title": "Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus Type II", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diabetes mellitus type 2;\n\n          -  HbA1c >7 % (stable f\u00fcr 6 months, max. variation of 0,5%)\n\n          -  stable oral antidiabetic therapy for 6 months with Metformin, Vildagliptin, Gliniden\n             or without oral Antidiabetics\n\n          -  age of 45 to <80 years (men and women)\n\n        Exclusion Criteria:\n\n          -  Myocardial infarction or stroke within the last 5 years\n\n          -  Therapy with acarbose\n\n          -  Acute peripheral arterial disease within the last 12 months\n\n          -  Instable metabolic situation\n\n          -  Uncontrolled hypertension\n\n          -  Body-Mass-Index \u2265 35 kg/m\u00b2\n\n          -  Smokers\n\n          -  Daily consumption of probiotic food\n\n          -  Malignant disease within the last 5 years\n\n          -  Status post transplantation\n\n          -  Immunosuppressive therapy within the last 3 months\n\n          -  Therapy with antibiotics\n\n          -  Macroalbuminuria\n\n          -  Severe liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144948", 
            "org_study_id": "PUNiDIA-2014"
        }, 
        "intervention": {
            "arm_group_label": "E.-coli-Nissle", 
            "description": "1 ml qd for 24 weeks", 
            "intervention_name": "e.-coli-nissle", 
            "intervention_type": "Drug", 
            "other_name": "Mutaflor"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "diabetes", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "antje.bergmann@uniklinikum-dresden.de", 
                "last_name": "Antje Bergmann, Prof. Dr. med.", 
                "phone": "0049351314439", 
                "phone_ext": "0"
            }, 
            "contact_backup": {
                "email": "katharina.schmidt@uniklinikum-dresden.de", 
                "last_name": "Uta-Katharina Schmidt-G\u00f6hrich", 
                "phone": "0049351314439", 
                "phone_ext": "0"
            }, 
            "facility": {
                "address": {
                    "city": "Dresden", 
                    "country": "Germany", 
                    "zip": "01307"
                }, 
                "name": "Carus-Hausarztpraxis"
            }, 
            "investigator": {
                "last_name": "Antje Bergmann, Prof. Dr. med", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study to Investigate the Effect of E-coli-nissle as Probiotic Adjuvant to Antidiabetic Standard Care in Patients With Diabetes Mellitus Type II", 
        "overall_contact": {
            "email": "martina.schulze@gwtonline.de", 
            "last_name": "Martina Schulze"
        }, 
        "overall_official": [
            {
                "affiliation": "Carus Hausarztpraxis on behalf of GWT-TUD GmbH", 
                "last_name": "Antje Bergmann, Prof. Dr. med.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum Dresden on behalf of GWT-TUD GmbH", 
                "last_name": "Stefan R. Bornstein, Prof. Dr. med", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Decrease in HbA1c levels", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144948"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in insulin resistance/secretion", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "change in lipid parameters", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "change in parameters of oxidative stress", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "change in gastrointestinal condition", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "GWT-TUD GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "ARDEYPHARM GmbH", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "GWT-TUD GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}